Connecting European Neuroscience

Michael Platten, MD

Programme Committee Member FENS Forum 2020

Curriculum Vitae

 

Professional and academic career

2016   Full Professor (W3) of Neurology, Heidelberg University and Chairman, Department of Neurology, University Hospital Mannheim

2015 – 2016   Full Professor (W3) of Neuroimmunology, German Cancer Research Center Heidelberg

2014 – 2016   Vice chair, Department of Neurology, Heidelberg Medical Center, University of Heidelberg

2013 – present   Head Clinical Cooperation Unit Neuroimmunology and BrainTumor Immunology, German Cancer Research Center

2010 – 2015   Associate Professor (W3) of Experimental Neuroimmunology, University of Heidelberg

2007 – 2013   Head Helmholtz University Young Investigator Group Experimental Neuroimmunology, German Cancer Research Center

2007 – 2014   Vice chair and senior attending, Department of Neurooncology, University of Heidelberg

2006 – 2007  Attending, Department of Neurology, University of Tübingen

2006    Habilitation in Neurology, University of Tübingen

2006    Board Certification in Neurology, University of Tübingen

2002 – 2004    Postdoc, Department of Immunology, Stanford University, USA

1999 – 2006    Residency in Neurology, University of Tübingen

1998    MD, Department of Neuropathology, University of Bonn

1991 – 1998    Medical School, University of Bonn (Germany), University of London (England) and Harvard Medical School 

Honours and awards 

2016    Honorary Member – European Academy of Tumor Immunology

2012    Sir Hans Krebs Award

2011    Chica and Heinz Schaller Award

2010    Heinrich Pette Award of the German Neurological Society

2006    Helmut Bauer Award for Multiple Sclerosis Research

2002 – 2004    Emmy Noether Fellow of the German Research Foundation

2000 – 2002    Jung Fellow

2000    Basic Young Scientist Award of the European Association of Neurooncology 

General administrative and organisational experience 

2018 – present            Board Member of the Heinrich Lanz Center for Personalized Medicine, Medical Faculty Mannheim

2018 – present            Member of the German Cancer Aid Advisory Board for the Promotion of Young Scientists

2018 – present            Management Board Helmholtz-Institute of Translational Oncology (HI-TRON)

2018 – present            Chair, Scientific Committee, European Association for Neuro-Oncology (EANO)

2017 – present            Spokesperson, Research Program Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University

2016 – present            Faculty member of the German Consortium for Translational Cancer Research (DKTK)

2015 – present            Head Immunomonitoring Unit, German Cancer Research Center

2014 – present            Executive Board member of the Neurooncology Working Group (NOA) of the German Cancer Society

2013 – present            Member of the Immunotherapy Research Review Committee, German Cancer Research Center

2012 – 2016    Member of the EORTC General Assembly 

Research interests

Neuroimmunology, Neurooncology 

Selected Publications

Bunse L*, Pusch S*, Bunse T*, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger M, Harter P, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende CM, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suva M, Niemeyer BA, von Deimling A, Wick W, Platten M (2018). Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. Nat Med 24:1192-1203. * equal contribution

Bunse L*, Schumacher T*, Sahm S*, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M (2015). Proximity ligation assay evaluates presentation of mutant isocitrate dehydrogenase 1 in gliomas. J Clin Invest 125:1-14. *equal contribution

Schumacher T*, Bunse L*, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M (2014). A vaccine targeting mutant IDH1 induces antitumor immunity. Nature 512:324-327. *equal contribution.

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011). An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature 478:197-203.

Platten M*, Ho PP*, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L (2005). Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310:850-855. *equal contribution

 

Michael Platten, MD

Heidelberg University
Medical Faculty Mannheim
Department of Neurology
Theodor-Kutzer-Ufer 1 – 3

loading